DRKS00025594已完成未知
Reduction of care-related risks for older patients during and post acute hospital care - ReduRisk
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 589
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 70 Years 至 one（—）
- 性别
- All
入选标准
- •acute inpatients = 70 years of age, increased risk for functional decline, immobility, falls, delirium, or rehospitalisation, informed consent
排除标准
- •Patients receiving palliative care in the final phase.
研究者
相似试验
已完成
不适用
Pro-active care for the older people at risk for functional decline: Screening for vulnerability and effectiveness of a subsequent guided care plan in primary careeerstelijns ouderengeneeskundeolder people with multiple problemsvulnerable elderlyNL-OMON33008eids Universitair Medisch Centrum10,000
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.EUCTR2016-002272-27-BESaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002272-27-ATSaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.EUCTR2016-002272-27-PTSaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible forhigh-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma infirst Relapse or Progression by adding Nivolumab to Gemcitabine,Oxaliplatin plus Rituximab in case of B-cell lymphoma.EUCTR2016-002272-27-PLSaarland University388